SCHEMBL829485

SCHEMBL829485

O=C(Oc1c(Cl)cc(Cl)cc1Cl)N1CCCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.63
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C19 P33261 1/20 0.63
NPSR1 Q6W5P4 3/20 0.61
ALDH1A1 P00352 5/20 0.53
TSHR P16473 3/20 0.51
LIPE Q05469 1/20 0.51
POLB P06746 3/20 0.50
SPR P35270 1/20 0.50
TDP1 Q9NUW8 2/20 0.48
SMN1; SMN2 Q16637 6/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 4/20 0.45
GAA P10253 3/20 0.45
LMNA P02545 3/20 0.45
GLA P06280 2/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830024 0.98 NPSR1 (0.64) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL829523 0.85 HRH4 (0.48) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL830533 0.82 KMT2A (0.59) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL829665 0.79 FAAH (0.53) MAPTKMT2AMEN1CYP1A2CYP2C19
Phenopylate SCHEMBL29493743 0.78 HTT (0.62) MAPTKMT2AMEN1CYP1A2CYP2C19
Phenopylate SCHEMBL10976218 0.78 HTT (0.62) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL4641481 0.77 CA1 (0.42) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL829345 0.76 LMNA (0.43) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL830249 0.76 HPGD (0.50) MAPTKMT2AMEN1CYP1A2CYP2C19
SCHEMBL828934 0.75 MAPT (0.55) MAPTKMT2AMEN1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 MAPT 3311/4885KMT2A 3045/4885MEN1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.